Human papillomaviruses (HPVs) are associated with a number of clinical conditions, of which the most serious is cervical carcinoma. The E6 protein of the oncogenic, mucosal-speci®c HPV types has been shown to complex with p53 and, as a result, target it for rapid proteasomemediated degradation. As a consequence, p53's growtharrest and apoptosis-inducing activities are abrogated. Since p53 is frequently wild type in cervical cancers, unlike other cancers in which it is often mutated, the notion has arisen that E6's activity with respect to p53 is equivalent to an inactivating mutation of p53. In addition, several studies have shown that the pathways both upstream and downstream of p53 are intact in cervical cancers; this suggests the potential importance of the E6 ± p53 interaction for therapeutic intervention. However, like all viral oncoproteins, E6 is a multifunctional protein and a plethora of other cellular targets has been identi®ed. Indeed, E6's interactions with some of these additional targets appear to be equally important in the pathogenesis of HPV, and may also represent valid targets for therapeutic intervention.
Introduction
The human papillomavirus (HPV) family is ubiquitous in the human population and more than 100 virus types have been identi®ed (de Villiers et al., 1997) . The viruses are small double-stranded DNA viruses with a genome of approximately 8 kb. The dierent HPV types are strictly epitheliotropic, and this tropism can be further subdivided into a cutaneous or a mucosal speci®city which can also extend to the precise anatomical site susceptible to infection. A number of these HPV types have been associated with a variety of clinical conditions, ranging in severity from cutaneous warts of the hands (HPV type 1) to squamous cell carcinomas in renal transplant recipients (HPV types 5 and 8) and to anogenital malignancies, most importantly cervical cancer (HPV types 16, 18, 31, 33 and 45) (zur Hausen and Schneider, 1987; zur Hausen, 1991) .
The overwhelming majority of cervical cancer patients show serological, histopathological or molecular evidence of prior infection with HPV, and viral DNA sequences can be detected in tumour tissue. Indeed, the tumours, and cell-lines derived from them, continue to express the viral E6 and E7 proteins, suggesting that these proteins are required for the continued growth of the cells (Schwarz et al., 1985; Smotkin and Wettstein, 1986; Androphy et al., 1987; Banks et al., 1987) . However clinically important the transforming activity of certain HPV types may be, it is also important to remember that the normal viral lifecycle is intended solely to replicate the virus; transformation occurs only as a mistake. Thus, dissection of the interactions between viral proteins and their cellular targets is important, both in the understanding of the normal viral life-cycle and the errors that result in neoplastic transformation, and in the search for potential therapeutic strategies.
HPV E6 proteins
The E6 proteins of HPV are approximately 150 amino acid polypeptides that have an apparent molecular mass of approximately 18 kD. The most characteristic feature of all HPV E6 proteins is the presence of four Cys-X-X-Cys motifs which permit the formation of two zinc ®ngers (Cole and Danos, 1987, Barbosa et al., 1989; Grossman and Laimins, 1989) . These motifs are strictly conserved in E6 proteins throughout the HPV family, and ablation of any one of them results in defective activity in all assays (Kanda et al., 1991; Sherman and Schlegel, 1996) . These zinc-®nger domains are preceded by a hydrophilic amino-terminal domain, are separated by a hydrophobic domain and are followed by a short carboxy-terminal domain, which in the case of the high-risk mucosal HPV types contains a PDZ-binding motif (Kiyono et al., 1997; Lee et al., 1997 ) that, in turn, contains an overlapping protein kinase A (PKA) site (KuÈ hne et al., manuscript in preparation).
The E6-mediated degradation of p53 p53 was initially identi®ed through its association with another DNA tumour virus protein, SV40 TAg (Lane and Crawford, 1979; Linzer and Levine, 1979) , and it is also found in association with the adenovirus E1B 55 k protein (Sarnow et al., 1982) . Both of these interactions result in the formation of stable complexes between the viral proteins and p53. In contrast, attempts to detect p53 protein in HPV-transformed cell lines, such as HeLa, were initially unsuccessful, although high levels of p53 mRNA were detected (Matlashewski et al., 1986; Band et al., 1991) . This suggested either that translation of p53 mRNA was in some way repressed, or that the turnover of p53 protein was increased in HPV-transformed cells. The second hypothesis was eventually proven correct through in vitro analyses of the E6±p53 interaction. Werness et al. (1990) showed that the E6 proteins from HPV-16 and HPV-18 are able to bind to p53, and it was further shown that this binding promotes the degradation of p53 via the ubiquitin pathway (Schener et al., 1990) . Subsequent work showed that the E6-mediated degradation of p53 is dependent upon a cellular protein, E6-associated protein (E6-AP), also known as UBE3A, (Huibregtse et al., 1991 , 1993a , Schener et al., 1993 . This protein is a monomeric 100 kD polypeptide that acts as an E3 ubiquitin-protein ligase. In the ubiquitination cascade, E1 proteins activate ubiquitin which is then transferred by E2 conjugating enzymes to E3 ubiquitin-protein ligases which recognise speci®c target proteins (Hershko and Ciechanover, 1992) . A schematic diagram of this cascade, as it is thought to involve E6, p53 and E6-AP, is shown in Figure 1 . Interestingly, mutants of E6-AP that cannot bind E6 are also unable to interact with p53 (Huibregtse et al., 1993b) , and mutant p53 proteins that cannot bind to E6 are not susceptible to E6-AP-induced degradation (Schener et al., 1992) , indicating that E6 is required to mediate the p53/E6-AP interaction. More recent studies using antisense inhibition of E6-AP have shown that p53 levels only increase in cells expressing E6 (BeerRomero et al., 1997) , suggesting that E6-AP is probably not normally involved in p53 degradation; in addition, use of a ®ssion yeast expression system has shown an absolute requirement for both E6 and E6-AP to obtain degradation of p53 (Waddell and Jenkins, 1998) . Thus, the E3 ligase in the p53 degradation cascade is not simply E6-AP, but must be an E6-AP/E6 complex. However, E6-AP does not require E6 in order to function as a ubiquitin-protein ligase, since it has been shown that E6-AP alone is capable of ubiquitinating itself and a number of other cellular proteins (Nuber et al., 1998) and that E6-AP, in fact, belongs to a family of closely related ubiquitin ligases (Huibregtse et al., 1995; Schwarz et al., 1998) . E6 has since been shown to stimulate the degradation of both c-Myc and Bak through the interaction with E6-AP (GrossMesilaty et al., 1998; Thomas and Banks, 1998) , but in these cases it appears to be an enhancement of a normally occurring interaction. In the degradation of p53, E6 appears to have diverted E6-AP to an unnatural target.
It has been assumed that the degradation of p53 contributes to the oncogenic potential of the high risk Figure 1 HPV E6 induces the degradation of p53. The E1 ubiquitin-activating enzyme activates ubiquitin (Ub), which is transferred by the E2 ubiquitin-conjugating enzyme to the E3 ubiquitin-protein ligase. HPV E6 binds to E6-AP, forming an E3 enzyme which speci®cally binds and ubiquitinates p53. The polyubiquitinated p53 is then degraded by the 26S proteasome complex p53 and E6 in HPV pathogenesis M Thomas et al HPVs, although several studies have shown that mutants of E6, defective in their ability to induce the degradation of p53, can still immortalize human embryonic cells (Ishiwatari et al., 1994; Nakagawa et al., 1995) , can co-operate with activated ras to transform primary baby rat kidney cells and can transform established murine cells (Inoue et al., 1998) . In addition, although the E6 proteins of high-risk cutaneous HPV types 5 and 8 have been shown to be necessary for immortalization of rodent ®broblasts (Iftner et al., 1988; Schmitt et al., 1994) , they have not been shown to interact with p53 (Elbel et al., 1997) . Interestingly, the E6 protein from HPV-1, which is clinically classi®ed as low-risk, has been shown to inhibit p53 transactivation (Kiyono et al., 1994) . Thus, although it seems improbable that E6-induced degradation of p53 has no role in the development of HPV-associated malignancies, other functions of E6 must also be involved.
E6±p53 binding: alternatives to degradation
Soon after the ability of E6 to induce the degradation of p53 was recognized, it was also shown that E6 could interfere with p53 function through additional and distinct mechanisms. E6 proteins from both highand low-risk HPVs were shown to be capable of binding to p53 without inducing its degradation (Crook et al., 1991a; Lechner and Laimins, 1994) . This interaction prevents the p53-mediated transcriptional repression of TATA-containing promoters (Lechner et al., 1992) , and also represses p53's transactivation of promoters containing p53-responsive elements . This observation was in part explained by the ®nding that when E6 binds to p53, it prevents p53 from binding to a number of its DNA recognition motifs (Lechner and Laimins, 1994; Thomas et al., 1995) .
Some controversy arose over the years about which regions of the E6 protein were necessary for interactions with p53. Dierent mutational analyses had de®ned dierent regions of HPV-16 E6 as essential for p53 binding and p53 degradation (Crook et al., 1991a; Mietz et al., 1992) . Although this was partly resolved by the use of a series of HPV-18 E6 mutants , the problem was compounded by the fact that these studies used in vitro assays which have since been shown to be not altogether representative of the in vivo situation (Foster et al., 1994; Crook et al., 1996; Gardiol and Banks, 1998) . A more recent analysis by Li and Cono (1996) showed that two regions of p53 can be bound by E6: a region in the carboxy terminus between amino acids 376 ± 384 is bound both by benign HPV-6 and by oncogenic HPV-16 E6, but this binding has no eect upon p53 stability; while HPV-16 but not HPV-6 E6 can bind to the core region, (amino acids 66 ± 326) which correlates with the induction of p53 degradation. This study also used chimaeric E6 proteins (Crook et al., 1991a) to demonstrate that the C-terminal half of E6 can bind to p53 but that the N-terminal half is required to induce degradation. This is also con®rmed by more recent data showing that the N-terminal 43 amino acids of E6 are required for binding to E6-AP .
A natural consequence of the E6-induced degradation of p53 is the inhibition of p53's growth arrest and apoptotic functions. Indeed, within cervical tumours, unlike most other cancers, p53 is almost invariably wild type (Crook et al., 1991b; Schener et al., 1991) , perhaps indicating that the eects of E6 are analogous to an inactivating mutation. This possibility was supported by studies showing that pathways leading to p53 activation are functional in cells derived from cervical tumours (Butz et al., 1995 (Butz et al., , 1996 . This has led to the notion that blocking E6-mediated degradation of p53 might be sucient to reactivate p53 function in these cells. However this is not necessarily the case: recent studies have shown that inhibition of E6-induced p53 degradation does not always give rise to elevated levels of p53 within such cervical tumour cells. Additional DNA-damaging agents also appear to be required to fully restore p53 levels (Mantovani and Banks, 1999) . This implies that, in some cervical tumour cells, the intrinsic signals necessary for activating p53 are lacking and these need to be provided by additional stimuli. In addition, as can be inferred from the above-mentioned mutational analyses, merely blocking E6-mediated degradation of p53 might not be sucient to overcome all the deleterious eects of E6 upon p53. Indeed, in cervical cell lines, although blocking E6-induced degradation of p53 frequently results in increased levels of p53 protein, the subsequent correct nuclear localization of p53 appears to be perturbed (Mantovani and Banks, 1999) . Taken together, these observations suggest that strategies aimed at the therapeutic targeting of the E6±p53 interaction would be most likely to succeed if the actual physical association between E6 and p53 could be disrupted.
Finally, it is also worth noting that once cervical tumour cells metastasise, mutations within p53 become more frequent . This seems to indicate that the presence of mutant p53 may give a cell a competitive advantage over cells in which p53 activity is merely abrogated by E6; this also tends to provide support for the idea that mutants of p53 can have a dominant±negative phenotype.
Dierences in the replication of high and low-risk HPVs
It is, perhaps, surprising that the high-risk HPV E6s interact so eectively with p53 compared with the E6s from low-risk HPVs, since one would expect that both groups of viruses must overcome similar cellular restrictions to achieve a full cycle of viral replication. The reason for the dierence probably lies in their respective sites of replication. All HPVs infect keratinocytes in the basal layers of the epidermis, but they replicate only in dierentiating epithelium and the virus requires cellular DNA replication proteins in order to replicate its own DNA. For a cell to enter a state of terminal dierentiation it must exit the cell cycle and cease DNA replication and, since the response of such a cell to inappropriate DNA replication is p53-induced apoptosis, the virus has to perform a biochemical balancing act; stimulating DNA replication whilst inhibiting apoptosis. However, the low-and highrisk HPVs dier, both spatially and temporally, in p53 and E6 in HPV pathogenesis M Thomas et al their sites of DNA replication within the differentiating epithelium (Doorbar et al., 1997) . The lowrisk HPV types generally replicate only in the lower levels of the strati®ed epithelium where the keratinocytes are still undergoing cell division. In contrast, the high-risk HPVs replicate their genomes in the higher levels of the epithelium where the keratinocytes have fully entered the process of terminal dierentiation; in these cells the cellular DNA replication is switched o as the cells are not in the cell cycle. Thus the high-risk virus types may have to stimulate cells to replicate DNA in a more unnatural environment than the low-risk types. Therefore, the high-risk HPV types require their E7 proteins to more eectively modulate the induction of DNA synthesis (Sato et al., 1989; Banks et al., 1990) and, consequently, require their E6 proteins to more eectively ablate the p53 response.
Eects of E6 upon cell cycle
Transformed cells expressing HPV-16 or HPV-18 E6 lose the G1 checkpoint activity very early, presumably due to the degradation of p53 (Dulic et al., 1994) , and are also resistant to p53-induced growth arrest and apoptosis as a result of DNA damage (Kessis et al., 1993; Foster et al., 1994; Pan and Griep, 1995; Thomas et al., 1996; Cai et al., 1997) . The G2 checkpoint is initially unaected (Paules et al., 1995) but there is increased chromosomal instability in E6-expressing cells over time, and this is probably caused by the observed attenuation of the G2 checkpoint function (White et al., 1994; Kaufmann et al., 1997) . This may be caused by E6's altering of cyclin/cdk complexes (Xiong et al., 1996) , or may relate to the ablation of a p53-regulated G2/ M checkpoint (Stewart et al., 1995; Hermeking et al., 1997) . HPV-16 E6 aects the G2/M checkpoint controls in a number of ways (Thompson et al., 1997) . In IMR-90 cells stably expressing E6, the G2 delay in response to ionizing radiation is considerably reduced, probably owing to the observed increase in the concentrations and activities of cdc2, cyclin A and cyclin B. In these cells, okadaic acid and caeine can induce premature chromosome condensation, indicating that the checkpoint that couples M-phase entry to the completion of DNA replication has also been ablated. These cells also accumulate a DNA content of greater than 4 N in the presence of nocodazole, indicating that the mitotic spindle checkpoint is also disregulated. Abrogation of the mitotic spindle checkpoint has also been reported in E6-expressing human foreskin keratinocytes (HFKs) (Thomas and Laimins, 1998) and these cells, not surprisingly, have very low p53 levels. However, this study also found that HFKs expressing E7 exhibited an abrogation of mitotic spindle checkpoint activity, despite expressing high levels of transcriptionally active p53. This correlates with data suggesting that the mitotic spindle checkpoint does not act eectively in cells which lack either p53 or pRb proteins (Di Leonardo et al., 1997) , and it also demonstrates that the complementary activities of p53 and pRb are mirrored by the complementarity between E6 and E7 functions.
Cellular and viral protein polymorphisms
Although the sequences of a very large number of cellular and viral proteins have been determined, it is worth remembering that the so-called prototype sequence is not necessarily the only wild type version of that protein, nor, indeed, is it necessarily the most common. The human wild type p53 exhibits a sequence polymorphism in the general population that encodes either a proline (p53Pro) or an arginine (p53Arg) residue at position 72 and which results in a mobility dierence in the p53 protein on SDS ± PAGE. These two polymorphic forms appear to be functionally equivalent with respect to their interaction with SV40TAg (Moreau and Matlashewski, 1992) and neither type had been clearly associated with any increased cancer risk. However, it recently became clear that the polymorphism lies in a region of p53 that is necessary for the induction of apoptosis (Walker and Levine, 1996; Sakamuro et al., 1997) . This, naturally, gave rise to renewed interest, particularly since the p53Arg polymorphism ablates one of the ®ve PxxP SH3-binding domains (Yu et al., 1994) found in this region. It was recently shown that p53Arg is considerably more susceptible than p53Pro to the degradation induced in vivo by HPV-18 E6 and HPV-16 E6 . In addition, the low-risk HPV-11 E6 was also shown to be able to induce the degradation of p53Arg, but not p53Pro. A recent biochemical analysis of p53Pro and p53Arg has shown that p53Pro is approximately twice as strong a transcriptional activator as p53Arg , but that p53Arg is approximately twice as eective in preventing immortalization of primary rodent cells. Since the prevention of immortalization in such cells has been shown to be dependent on the induction of apoptosis (Crook et al., 1994; Thomas et al., 1996) , it is tempting to speculate that p53Arg may be more eective in inducing apoptosis and hence more dangerous to the continued replication of the virus. However, it is not yet clear quite how important these two polymorphisms may be in the development of cervical cancer, since there have been con¯icting reports Rosenthal et al., 1998) . It may therefore be necessary to look at the p53Pro and p53Arg in the context of dierent polymorphic variants of the HPV E6 protein, or other polymorphisms in key cellular genes involved in tumour suppression. Many intratypic HPV variants have been identi®ed, which can have up to 2% DNA sequence variation in some open reading frames (Bernard et al., 1994) . The prevalence of any one of the variants diers, depending upon the geographical locations and populations studied (Yamada et al., 1997) . Some HPV types may also be more prone to variation than others: one report suggests that the number of variants of HPV-5 and HPV-8 E6 proteins found in one location is considerably higher than the number of HPV-16 E6 variants (Deau et al., 1991) . The majority of the studies of HPV-16 E6 function have been performed upon the prototype protein, but it is becoming clear that certain variants may dier signi®cantly in their activities. It was recently shown, in one study, that although the prototype HPV-16 E6 was present in 44% of CINIII lesions, it was found in less than 10% of invasive cervical carcinomas (Zehbe et al., 1998) , 1996) and that this correlates, at least partly, with their ability to induce the degradation of p53 in vitro. It is therefore clear that there are clinically relevant dierences between the variant and prototype E6 proteins, and these probably re¯ect quantitative dierences in their biochemical activities with respect to their cellular target proteins. A systematic analysis of the interactions of prototype and variant E6 proteins with both of the polymorphic forms of p53 and with E6-AP may shed some light on these dierences.
The E6* proteins
As we have discussed above, the exact nature of the E6±p53 interaction can vary according both to HPV type, and to intratypic variations in E6 sequence. In addition, the alternatively spliced variants of E6, the E6* proteins, provide a potential mechanism by which the E6±p53 interaction might be modulated by the virus itself. The high-and low-risk HPVs dier markedly in their early region transcription patterns (Smotkin et al., 1989) , as can be seen in Figure 2 . High-risk HPV transcription patterns involve a number of alternative splices which generate a complex pattern of mRNAs (Doorbar et al., 1990) . The regulation of these splicing events during normal viral infection is not yet understood, but the majority involve both a splice-donor site, whose position at approximately 130 base pairs into the E6 reading frame is highly conserved throughout the high-risk HPV types, and a series of downstream splice-acceptors. Amongst the polypeptides encoded by such transcripts is a series of, typically four, truncations of the full-length E6 protein (called E6*I-IV), which have become known as the E6* proteins. Since previous analysis of the function of HPV-16 E6*I had demonstrated no immortalization capacity in primary human keratinocytes, it was Figure 2 Alternative splicing in the generation of E7, E6 and E6* transcripts. The cartoon shows the dierences between the highand low-risk mucosal virus types in transcription of the E6-E7 genes. Low-risk virus genes are transcribed in a linear fashion whilst alternative splicing results in at least ®ve mRNA species in high-risk viruses. The structure of the alternatively spliced protein product, HPV-18 E6*I, is shown below, indicating the region that is involved in binding the full-length E6 protein. The aminoterminal 43 amino acids are identical with those of the full-length protein; the carboxy-terminal 12 amino acids come from the alternative splicing into a dierent reading frame p53 and E6 in HPV pathogenesis M Thomas et al thought that the splicing event served merely to facilitate ribosomal entry and increase the eciency of E7 translation (Sedman et al., 1991) . However, more recent studies have suggested that E7 is translated equally eciently from spliced and unspliced transcripts (Stacey et al., 1995) ; and that mutation of the splice-donor site does not reduce the levels of E7-induced PCNA in a raft culture system (Cheng et al., 1995) , which suggests that E7 translation eciency is not dependent upon the E6* splicing event.
The function of E6* proteins
Although the E6* transcripts are abundant in both HPV-infected cells and in cell-lines derived from cervical tumours (Schneider-GaÈ dicke and Schwarz, 1986; Smotkin and Wettstein, 1986) , endogenous E6* protein has been detected only when HPV-18-containing cervical tumour cells were grown in nude mice (Schneider-GaÈ dicke et al., 1988) . When translated in vitro, E6* proteins are generally unstable (Shalley et al., 1996 ; DP, personal observations), suggesting that rapid turnover may explain the low levels of E6* protein observed in the cell. One of the possible functions of the E6* proteins was demonstrated by studies that showed that in vitro translated HPV-16 E6*IV (Shalley et al., 1996) and HPV-18 E6*I can inhibit the E6-directed, ubiquitin-mediated degradation of p53 in vitro. Assays in p53-null cells showed that coexpression of HPV-18 E6*I with p53 and full-length E6 resulted in an inhibition of E6-directed degradation of p53. The inhibition of p53 degradation upon E6*I expression, as measured by an increase in p53 transcriptional activity and in reduced cellular proliferation, was observed in cells containing both p53 and HPV E6 protein, but not in cells lacking either p53 or E6 . The means by which E6* is able to inhibit E6-induced p53 degradation is interesting. It has been shown that HPV-18 E6*I can bind in vitro to fulllength E6 and also to E6-AP, but not to p53 itself. A mutational analysis of HPV-18 E6*I has shown that the antiproliferative eects of E6* overexpression appear to correlate mainly with its ability to interact with the full length E6 protein, rather than with E6-AP (Pim and Banks, submitted for publication). This interaction presumably blocks the formation of the E6-AP/E6 E3 ligase that is speci®c for p53. These studies suggest that one function of the E6* proteins is to modulate the E6-mediated degradation of p53 during viral replication. The inhibition of p53's tumour suppressor function by HPV E6 is believed to predispose HPV-infected cells to genetic changes which can lead to malignant conversion. Immortalization and malignant progression are often associated with the integration of the virus DNA into the host cell genome, resulting in a loss of replicative competence. Therefore, the E6* proteins may represent a means of modulating the E6±p53 interaction, so as to reduce this risk. In addition to this model for E6* function, there is another potential reason why the E6±p53 interaction might need to be modulated, and this will be discussed below.
Viral DNA replication and p53
A number of reports have shown the association of p53 with the replication complexes of certain viruses. p53 has been shown to inhibit SV40 DNA replication by competing with TAg for binding to polymerase a (Braithwaite et al., 1987; Gannon and Lane, 1987) . In herpes simplex virus-infected cells p53 and pRb colocalize with the viral DNA replication compartments (Wilcock and Lane, 1991; Zhong and Hayward, 1997) , and although this might initially seem to be a further example of p53 acting to inhibit viral replication, it is not necessarily so. These studies also showed the colocalization of cellular replication proteins, including the DNA-binding protein RP-A, PCNA, polymerase a and DNA ligase 1, within these viral replication complexes, suggesting that the virus was making use of the cellular replication proteins, despite encoding a full repertoire of its own (Wu et al., 1988) . p53 levels have also been shown to increase in cytomegalovirus (CMV)-infected cells (Muganda et al., 1994 (Muganda et al., , 1998 Fortunato and Spector, 1998) and, again, p53 colocalizes with the CMV DNA replication compartments (Fortunato and Spector, 1998) . Since p53 associates with a number of DNA replicationassociated proteins and has been shown to modulate DNA replication by direct interaction with DNA replication origins (Bargonetti et al., 1991; Kanda et al., 1994; Cox et al., 1995; Miller et al., 1995) , two possibilities exist: the ®rst is that p53 is present in these complexes in an attempt to block viral DNA replication; the other possibility is that p53 is being used by the virus to aid in its DNA replication. There are variations in the extent to which the above-mentioned cellular proteins are associated with viral replication compartments, suggesting that the presence of p53 is independent, at least, of the presence of RP-A and they may, therefore, colocalize by a dierent mechanism. A recent report has suggested that p53 speci®cally inhibits the ampli®cation of papillomavirus DNA, but does not inhibit episomal maintenance, which occurs in synchrony with the cell cycle (Lepik et al., 1998) . The mechanism for this may be partly explained by the ®nding that p53 binds to the viral E2 protein (Massimi et al., submitted for publication). The E2 protein is not only the major viral transcriptional regulator (Bouvard et al., 1994) , but is also essential for viral DNA replication. Two of the four E2-binding sites found in the viral URR (upstream regulatory region) are located close to the viral origin of replication (ori) (Remm et al., 1992; Lu et al., 1993) ; E2, through its interaction with the viral ori-speci®c binding protein, E1, causes a local increase in E1 concentration at the viral ori, facilitating the initiation of viral DNA replication Stenlund, 1995, 1996) . It is possible that p53 might prevent this activity of E2, or may itself play a role in the viral DNA replication.
This raises the possibility that E6 activity, in addition to guarding against p53-induced apoptosis, is required to prevent p53 from inhibiting the ampli®cation of viral DNA. One could speculate that the E6* protein might release p53 to prevent a premature over-ampli®cation of the viral genome. Indeed, there has been a preliminary report that adenovirus 5 E4orf3 can temporarily release p53 from p53 and E6 in HPV pathogenesis M Thomas et al E1B inhibition (KoÈ nig et al., 1999) , which might suggest a further similarity in the functions of adenoand papillomavirus proteins.
At present it is impossible to decide whether p53 is present in viral replication complexes in an attempt to inhibit replication or because the virus has recruited p53 to assist replication. However, HPV requires DNA polymerase a for its own DNA replication (Kuo et al., 1994; Masterson et al., 1998; Conger et al., 1999) , and a recent study suggested that the intrinsic 3' ± 5' exonuclease activity of p53 is able to enhance the replicative ®delity of polymerase a (Huang, 1998) . This would seem to suggest that p53 may have been recruited by the virus in a proofreading capacity. It also appears that stimuli which activate p53's sequencespeci®c DNA binding activity may inhibit the 3' ± 5' exonuclease activity (Janus et al., 1999a) suggesting that, when`non-activated', p53 may be active in cooperating with polymerase a to eect DNA repair (Janus et al., 1999b) . This raises the interesting question of whether only certain modi®ed forms of p53 are targeted for degradation by E6. It is intriguing that p53 appears to be in some way involved with a large number of dierent DNA tumour viruses at the level of viral DNA replication and suggests that there may yet be further layers of complexity in the E6±p53 relationship.
Other targets of E6 ± a cautionary note
From the above discussion it is clear that a major function of E6 is the abolition of p53 activity, during certain stages of viral replication, and that this probably contributes towards tumorigenesis. However, it should also be borne in mind that E6 is a multifunctional protein. This has perhaps been forgotten in numerous studies which have assumed that overexpression of E6 only aects p53 function; this is not the case. The number of known E6 target proteins is increasing very quickly and the regions of E6 known to be involved in some of these interactions are shown in Figure 3 .
Recent studies have shown an interaction between E6 proteins and hDlg/SAP97 (DLG) protein (Lee et al., 1997; Kiyono et al., 1997) . This protein is a PDZdomain containing protein and is the mammalian homologue of the Drosophila discs large protein (dlg). The PDZ domains recruit plasma membrane and cytoskeletal proteins to regions of cell±cell contact; PDZ-containing proteins, such as DLG also possess other protein motifs, such as SH3 domains, through which they may mediate association between cytoskeletal and signalling molecules. The binding site for DLG is at the extreme carboxy terminus of E6; mutations within this region abolish degradation of DLG but the ability of E6 to degrade p53 is retained, indicating that quite dierent pathways are involved (Gardiol et al., submitted) . Thus it is interesting to note that, although HPV-16 E6 is a stronger inducer of p53 degradation than HPV-18 E6 Schener et al., 1990) , the prognosis for patients with HPV18-containing cervical carcinoma is poorer than that for individuals with HPV16-containing cancer (Burnett et al., 1992; Zhang et al., 1995) . The only correlation with this ®nding so far seems to be the capacity of the two dierent E6 proteins to target DLG for degradation. Thus, HPV-18 E6 contains a better consensus DLG-binding motif (Kiyono et al., 1997) , and is signi®cantly more active in inducing DLG Figure 3 The regions of the HPV-18 E6 protein that are known to be required for binding to some of its cellular target proteins, together with the site of phosphorylation by protein kinase A (PKA) p53 and E6 in HPV pathogenesis M Thomas et al degradation, than HPV-16 E6 (Gardiol et al., submitted) . Since DLG has been implicated in the control of cell ± cell contact and cell polarity (Lue et al., 1994; Woods et al., 1996) , it is reasonable to speculate that this activity of E6 might be relevant for tumour progression. Another PDZ-domain-containing protein has also recently been shown to be a target for E6-induced degradation, but this protein does not appear to be bound by E6 through the PDZ motif (Gao et al., 1999) . Homology analysis of this E6-targeted protein 1 (E6TP1) suggests that it might be a negative regulator of Rap1 GTPase and could therefore be involved in the negative regulation of mitogenic signalling. The E6-induced degradation of E6TP1 might restore this signalling and thence contribute to cellular immortalization. In this case HPV-16 E6 binds more strongly to E6TP1 than HPV-18 E6, suggesting that the mechanism of interaction is dierent from that with DLG. In view of E6's ability to bind and degrade DLG and E6TP-1 it is interesting that HPV-16 E6 has also been reported to bind to paxillin, but not to induce its degradation (Tong and Howley, 1997) . Paxillin is involved in signal transduction between the plasma membrane and focal adhesions and the cytoskeleton, and it is activated by tyrosine phosphorylation in response to a number of mitogenic stimuli (Rankin and Rosengurt, 1994) . It is possible that E6-induced disruption of the cytoskeleton and consequent interference with signal transduction can release the cell from certain cell cycle controls (Tong and Howley, 1997) . E6 binding without degradation also appears to occur in the case of an ERC-55 homologue, E6BP (Chen et al., 1995) . This is a calcium binding protein that appears to be a Vitamin D receptor (VDR)-associated factor (Imai et al., 1997 ) and E6's interaction may perhaps prevent the mediation of Vitamin D3's growth suppressive eects. Although neither the role of E6BP, nor the eect of E6's binding it, is fully understood, activation of VDR expression in the epidermis has been associated with cellular dierentiation (Zineb et al., 1998) and E6 can induce resistance to calcium-induced dierentiation in human keratinocyes (Sherman and Schlegel, 1996) . E6-induced ubiquitin-mediated degradation is clearly important in overcoming the apoptotic activities of p53, however E6 has also been shown to overcome p53-independent apoptosis (Pan and Griep, 1995; Steller et al., 1996) . It has recently been shown that this is, at least in part, the result of E6-induced ubiquitin-mediated degradation of the c-Myc and Bak proteins, both of which are associated with the induction of apoptosis (Gross-Mesilaty et al., 1998; Banks, 1998, 1999) . c-Myc is a well established cellular oncogene (Bouchard et al., 1998) whose overexpression can cause apoptosis (Askew et al., 1991; Evan et al., 1992) , probably through its activation of p14 ARF . This protein binds mdm2 and prevents its ubiquitinating p53 (Honda and Yasuda, 1999) , thus increasing p53 halflife Stott et al., 1998; Chin et al., 1998) and resulting in the possible induction of apoptosis. Conversely the downregulation of c-Myc has been shown to be required to promote differentiation (Pietenpol et al., 1990; Freytag et al., 1990) . Bak is a pro-apoptotic member of the Bcl-2 family of proteins and is highly expressed in the upper epithelial layers (Krajewski et al., 1996) , where HPV replicates. Since HPV replicates only in dierentiating epithelium the degradation of c-Myc could be required both to allow the induction of dierentiation, and to reduce any risk of c-Myc-induced apoptosis; the degradation of Bak might then be required to prevent or delay the induction of apoptosis in the dierentiating epithelium. Interestingly, both c-Myc and Bak exert their eects as partners in heterodimeric equilibria: thus, cMyc activates transcription as a heterodimer with its partner, Max; however, transcription from the same promoters can be repressed by Max-Mad heterodimers (Amati et al., 1992; Kretzner et al., 1992) . The Bcl-2 proteins promote or prevent entry into apoptosis by the formation of hetero-or homo-dimers between proand anti-apoptotic members of the family (Reed, 1998, for review) . Thus the degradation of c-Myc and of Bak induced by E6 could have profound eects upon these equilibria and this is a point that is frequently ignored with such viral proteins. Apparently minor modifications of crucial control equilibria within the cell could have quite major downstream eects on the regulation of cellular homeostasis.
HPV E6 proteins have also been implicated in processes resulting in perturbation of chromosomal structure and the control of normal cellular DNA replication. HPV-18 E6 has been shown to induce the ubiquitin-mediated degradation of Mcm7, via E6-AP (KuÈ hne and . The Mcm7 protein is a part of the replication licensing factor whose binding to cellular DNA replication origins (oris) ensures that each ori ®res only once in each round of DNA replication (Blow, 1993; ThoÈ mmes et al., 1997) . In addition, HPV-16 E6 has been shown to speci®cally upregulate telomerase activity during immortalization (Klingelhutz et al., 1996; StoÈ ppler et al., 1997; Filatov et al., 1998; Kiyono et al., 1998) . Indeed, mutational analysis of E6 has shown that the upregulation of telomerase, rather than the degradation of p53 is important for its immortalizing activity. How the perturbation of these processes aects viral replication is not yet apparent, however, it is not dicult to envisage how these activities may contribute to E6's transforming capability.
In summary, HPV E6 has been shown to be capable of interfering with the cellular controls of DNA replication, through Mcm7; chromosomal structure, through telomerase; cytoskeletal structure, through paxillin; cell polarity, through DLG; signal transduction, through E6TP1, paxillin, c-Myc and E6BP; dierentiation, through E6BP and c-Myc; and apoptosis, through Bak and c-Myc. The majority of these activities, with the probable exception of the c-Myc/ p14 ARF pathway, are independent of E6's activities with respect to p53. Since it is clear that many of the eects seen in cells upon overexpression of E6 are not related solely to the degradation of p53, extreme care is required in interpreting the results of p53 studies performed in cells expressing HPV E6.
Conclusion
Despite the above caveat, it is clear that a major function of E6, in conjunction with the hijacked E6-AP p53 and E6 in HPV pathogenesis M Thomas et al and with the E6* proteins, is the control of p53 activities to assist in the successful replication of the virus. It is also clear that failure by the virus to balance p53 levels can result in cellular immortalization and tumorigenesis. Therefore, although HPV E6 proteins have other important cellular targets, the E6±p53 association is undoubtedly of fundamental importance in the pathogenesis of HPV and it will continue to represent an important therapeutic target for the control and eradication of a number of important human cancers.
